Rigel (RIGL) Receives a Buy from H.C. Wainwright

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Rigel (NASDAQ: RIGL), with a price target of $7.50. The company’s shares closed yesterday at $3.35.

Pantginis commented:

“Valuation and impediments to achieving price target. We reiterate our Buy rating and $7.50 price target. Our target is based on our clinical net present value (NPV) model, which derives its value from Tavalisse without any current contribution from pipeline assets. This model allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Factors which could impede reaching our price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway.”

According to, Pantginis has 0 stars on 0-5 star ranking scale with an average return of -5.8% and a 37.2% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, Applied Genetic Technologies, and Iovance Biotherapeutics Inc.

Currently, the analyst consensus on Rigel is a Strong Buy with an average price target of $8, representing a 138.8% upside. In a report released yesterday, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $9 price target.


See today’s analyst top recommended stocks >>

Based on Rigel’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $25.56 million. In comparison, last year the company had a GAAP net loss of $17.66 million.

Based on the recent corporate insider activity of 8 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of RIGL in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. It focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms.

From Our Partners